AHA GUIDELINES Bundle (free trial)

Chronic Coronary Disease 2023

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1504138

Contents of this Issue

Navigation

Page 46 of 65

47 Linked Pharmacotherapy Baseline therapy: Consider aspirin, statin, and ACEi therapy in all patients. Sublingual nitroglycerin as needed. Smoking cessation and lifestyle changes. Antianginal Rx First line: Beta blocker (eg, carvedilol 6.25 mg BID uptitrated) Second line: CCB substituted (non DHP [eg, verapamil 40 mg BID titrated]) where beta blockers are not tolerated or ineffective. Third line: Add-in therapy CCB-DHP (eg, amlodipine) — only for those on beta blockers Nicorandil* (5 mg BID, uptitrated) Ranolazine (375 mg BID, uptitrated) Baseline therapy: If atherosclerosis or endothelial impairment, aspirin and statin should be considered. Sublingual nitroglycerin as needed. Smoking cessation and lifestyle changes. Antianginal Rx First line: CCB (eg, verapamil 40 mg BID uptitrated) Second line: Add long-acting nitrate (eg, isosorbide monotitrate 10 mg BID) Third line: Change nitrate to nicorandil* (eg, nicorandil 5 mg BID) Baseline therapy: Consider aspirin, statin and ACEi therapy in all patients. Sublingual nitroglycerin as needed.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Chronic Coronary Disease 2023